Novo Nordisk Faces Dual Challenges Amid Strategic Shifts

The Danish pharmaceutical giant Novo Nordisk is navigating a complex period marked by operational restructuring and legal scrutiny. As the company advances the U.S. launch of its oral Wegovy tablet, it confronts new job cuts and a significant antitrust lawsuit related to its diabetes portfolio.

Antitrust Allegations Surface Over Victoza

A new legal challenge emerged last Friday when a class-action lawsuit was filed against Novo Nordisk in a U.S. federal court in New York. The complaint alleges anticompetitive practices concerning the diabetes drug Victoza.

Plaintiffs accuse Novo Nordisk and Teva Pharmaceuticals of engaging in a “pay-for-delay” agreement. This alleged deal purportedly pushed back the market entry of more affordable generic versions until 2024, artificially maintaining higher drug prices. The suit seeks unspecified damages for purchasers of the medication.

Operational Restructuring Leads to Job Cuts

Simultaneously, Novo Nordisk is implementing further workforce adjustments. According to reports from the Danish industry publication Medwatch, the latest reductions will impact the pilot production unit, which develops active ingredients for clinical trials. The labor union Pharmadanmark confirmed the report on Monday.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The company did not provide specific figures regarding the scale of the cuts. In an official statement, Novo Nordisk referenced its strategy to maintain a flexible production network to ensure long-term growth. This move is part of a broader restructuring initiative that commenced in late 2025.

Strategic Focus on Oral Wegovy Rollout

On the commercial front, the firm’s current operational priority is the U.S. market introduction of the Wegovy tablet. In early January, pricing was disclosed: the starting dose will cost approximately $149 per month for cash-paying patients. Market analysts view the oral formulation as a critical component in Novo Nordisk’s rivalry with Eli Lilly. Initial prescription data from mid-January indicated a positive early uptake trend.

Investors reacted cautiously to the developments. Shares on the Copenhagen exchange closed slightly lower on Monday, trading at around 400.10 DKK, a decline of 0.31%. Market participants are now looking ahead to the release of fourth-quarter 2025 financial results on February 4. These figures are expected to provide insight into the financial impact of the ongoing restructuring and the preliminary commercial performance of the new oral weight-loss treatment.